Market Cap 530.17M
Revenue (ttm) 10.00M
Net Income (ttm) -29.47M
EPS (ttm) N/A
PE Ratio N/A
Forward PE N/A
Profit Margin N/A
Debt to Equity Ratio N/A
Volume 28,075
Avg Vol 812,584
Day's Range N/A - N/A
Shares Out 140.26M
Stochastic %K 30%
Beta 0.88
Analysts Strong Sell
Price Target $6.80

Company Profile

Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom, the United States, and internationally. It develops Etigilimab, an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for use in the treatment of tumors. The company is also developing Navicixizumab, which has completed Phase 1b clinical trials for the treatment of the late line ovarian ca...

Industry: Biotechnology
Sector: Healthcare
Phone: 44 33 3023 7300
Address:
One Cavendish Place, 4th Floor, London, United Kingdom
Svetli_stock
Svetli_stock Mar. 20 at 8:49 PM
0 · Reply
LDT79
LDT79 Mar. 20 at 8:11 PM
$MREO go to hell - never ever trust a DEI CEO
0 · Reply
Crivit
Crivit Mar. 20 at 8:56 AM
$MREO https://x.com/ej23ny/status/2034688359704981570?s=46&t=bEBIliluVsTI7poV3L9h2Q
1 · Reply
SebNo1234
SebNo1234 Mar. 20 at 7:47 AM
$MREO https://www.investing.com/news/analyst-ratings/mereo-biopharma-stock-maintained-at-buy-by-btig-on-regulatory-pathway-93CH-4571789
0 · Reply
ParallelPort
ParallelPort Mar. 19 at 4:32 PM
$MREO So good news first, it broke the .35 resistance but bounced right back and held. Institutions are cash dry to by so they can only hold it up on low volume days. Got earnings a week early, here is something that caught my eye in the report. Management has re-emphasized the "totality of the data," highlighting significant gains in Bone Mineral Density (BMD) and a reduction in vertebral fractures, stating these results "may provide the basis for engagement with the regulatory agencies." With words like "may provide" that doesn't sound very positive. And yesterday actual material news from one of the lawsuits.The lawsuit specifically targets the "BMD-to-Fracture" correlation. It claims management touted a 67% reduction in Phase 2 data while allegedly knowing the data lacked the control groups necessary to establish causation. This is the first specific accusation named in any suit which spooked investors and helped drop the price yesterday. Maybe "may provide" is because of lawsuits.
0 · Reply
ParallelPort
ParallelPort Mar. 19 at 2:23 PM
$MREO Will post around lunch the reasons for the drop. Couple of interesting tidbits from the last two days to catch you up on.
0 · Reply
Teamtalk2014
Teamtalk2014 Mar. 19 at 1:44 PM
$MREO Earliest yearly results. Missed Leerink recently while Ultragenx presented, website appears relatively static with partial metadata visible.
0 · Reply
davedtire
davedtire Mar. 19 at 12:59 PM
$MREO https://elite.finviz.com/news/338678/mereo-biopharma-reports-full-year-2025-financial-results-and-provides-corporate-highlights
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Mar. 19 at 12:42 PM
$MREO RSI: 39.81, MACD: -0.0380 Vol: 0.02, MA20: 0.40, MA50: 0.44 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
LDT79
LDT79 Mar. 18 at 3:48 PM
$MREO what a shit show and CEO is still there
0 · Reply
Latest News on MREO
Mereo BioPharma Provides Update on Lead Clinical Programs

Jan 12, 2025, 11:05 AM EST - 1 year ago

Mereo BioPharma Provides Update on Lead Clinical Programs


Svetli_stock
Svetli_stock Mar. 20 at 8:49 PM
0 · Reply
LDT79
LDT79 Mar. 20 at 8:11 PM
$MREO go to hell - never ever trust a DEI CEO
0 · Reply
Crivit
Crivit Mar. 20 at 8:56 AM
$MREO https://x.com/ej23ny/status/2034688359704981570?s=46&t=bEBIliluVsTI7poV3L9h2Q
1 · Reply
SebNo1234
SebNo1234 Mar. 20 at 7:47 AM
$MREO https://www.investing.com/news/analyst-ratings/mereo-biopharma-stock-maintained-at-buy-by-btig-on-regulatory-pathway-93CH-4571789
0 · Reply
ParallelPort
ParallelPort Mar. 19 at 4:32 PM
$MREO So good news first, it broke the .35 resistance but bounced right back and held. Institutions are cash dry to by so they can only hold it up on low volume days. Got earnings a week early, here is something that caught my eye in the report. Management has re-emphasized the "totality of the data," highlighting significant gains in Bone Mineral Density (BMD) and a reduction in vertebral fractures, stating these results "may provide the basis for engagement with the regulatory agencies." With words like "may provide" that doesn't sound very positive. And yesterday actual material news from one of the lawsuits.The lawsuit specifically targets the "BMD-to-Fracture" correlation. It claims management touted a 67% reduction in Phase 2 data while allegedly knowing the data lacked the control groups necessary to establish causation. This is the first specific accusation named in any suit which spooked investors and helped drop the price yesterday. Maybe "may provide" is because of lawsuits.
0 · Reply
ParallelPort
ParallelPort Mar. 19 at 2:23 PM
$MREO Will post around lunch the reasons for the drop. Couple of interesting tidbits from the last two days to catch you up on.
0 · Reply
Teamtalk2014
Teamtalk2014 Mar. 19 at 1:44 PM
$MREO Earliest yearly results. Missed Leerink recently while Ultragenx presented, website appears relatively static with partial metadata visible.
0 · Reply
davedtire
davedtire Mar. 19 at 12:59 PM
$MREO https://elite.finviz.com/news/338678/mereo-biopharma-reports-full-year-2025-financial-results-and-provides-corporate-highlights
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Mar. 19 at 12:42 PM
$MREO RSI: 39.81, MACD: -0.0380 Vol: 0.02, MA20: 0.40, MA50: 0.44 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
LDT79
LDT79 Mar. 18 at 3:48 PM
$MREO what a shit show and CEO is still there
0 · Reply
pakin2
pakin2 Mar. 17 at 2:12 PM
$MREO The lawsuit will also include Rare, who had the results first and were also very optimistic, right?
0 · Reply
biokvint
biokvint Mar. 17 at 1:56 PM
$MREO It is a common case of lawsuits when phase 3 fails. Besides surrogate end points have being achieved. This could be used for the way forward.
0 · Reply
11thestate
11thestate Mar. 17 at 11:31 AM
The more we dig into $MREO , the more shocked we are by what’s been hidden for years: https://11th.com/cases/mereobiopharma-investor-suit
0 · Reply
grod86
grod86 Mar. 16 at 3:14 PM
$MREO and like always, no meaningful news will happen during those dates.
1 · Reply
grod86
grod86 Mar. 16 at 12:19 PM
$MREO another day another nothing
0 · Reply
ParallelPort
ParallelPort Mar. 16 at 11:00 AM
$MREO Currently nothing going on here. Over 65% of the vol friday was in dark pools so this indicates institutions are practically done loading and are keeping the price pinned intentionally. Prob at least til after March options expire this week. We will see if there is any slight run next week going into earnings, til then prob just more of the same this week. But will keep an eye out for any material news and post when i get.
0 · Reply
LDT79
LDT79 Mar. 13 at 5:09 PM
$MREO get this fucking CEO out already!!!
1 · Reply
ParallelPort
ParallelPort Mar. 13 at 3:23 PM
$MREO Mereo Aug. 16th .50 calls just .10 each. Join in take a flyer. At that price low risk high reward🙂
1 · Reply
ParallelPort
ParallelPort Mar. 12 at 11:08 PM
$MREO I thought this might be interesting to anyone who didn't know already. This will make my work easier and help keep some a little more honest.
0 · Reply
ParallelPort
ParallelPort Mar. 12 at 11:06 PM
$MREO A significant regulatory change is coming on March 18, 2026. Under the "Holding Foreign Insiders Accountable Act," all Mereo directors and officers will be required to file Form 3, 4, and 5 reports moving forward. This will provide unprecedented transparency into their daily trading activity starting next week. The End of the "Foreign Loophole" Historically, directors and officers of foreign companies listed in the US (like Mereo, which is based in the UK) were exempt from Section 16 of the Exchange Act. The Old Way: If a Mereo director bought or sold shares, they only had to report it to the UK's Financial Conduct Authority (FCA). US investors often had to go hunting through foreign filings to find out what was happening. The New Way (March 18, 2026): The SEC is forcing foreign insiders to use the same Form 3, 4, and 5 system as US companies like Apple or Tesla.
0 · Reply
ParallelPort
ParallelPort Mar. 12 at 11:04 PM
$MREO Form 3 Initial Ownership: The first time an insider tells the SEC exactly how many shares they own. This is the "Audit." We will see exactly how much "skin in the game" every single director has right now. Form 4 Changes in Ownership: Must be filed within 2 business days of any buy or sell. No more "secret" selling. If a director dumps shares following a conference, you'll know in 48 hours. Form 5 Annual Wrap-up: Small transactions or gifts that weren't reported on a Form 4. Catches anything that might have slipped through the cracks during the year.
0 · Reply
Cajo_79_Silva
Cajo_79_Silva Mar. 12 at 1:20 PM
$MREO https://www.linkedin.com/posts/mereo-biopharma_last-week-wills-hughes-wilson-represented-activity-7437793407739105280-CAcS?utm_source=share&utm_medium=member_desktop&rcm=ACoAAAUAUAkBgNKfEucLfDqygpe_z5nxWKSiGpc
0 · Reply